Related Experiment Video
Updated: Aug 5, 2026

Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
Repurposing Small-molecule Inhibitors against Bunyaviruses: Advances, Mechanisms, and Therapeutic Prospects
Zhiqiang Liu1, Guoliang Chen1, Wu Zhong2
1School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Abstract:
Bunyaviricetes, including highly pathogenic members such as Severe Fever with Thrombocytopenia Syndrome Virus, Crimean-Congo Hemorrhagic Fever Virus, and Rift Valley Fever Virus, pose significant global health threats characterized by high mortality rates and a lack of approved specific therapeutics. Drug repurposing provides pharmaceutical companies with cost-effective and expedited strategies to discover innovative treatment options for patients. Given the issue of antiviral drug resistance and the high cost of developing new antiviral drugs, drug repurposing offers enormous potential for expanding the repertoire of available therapeutics. This paper reviews the progress made in developing candidate drugs against bunyaviruses through high-throughput screening and drug repurposing methods, summarizes the mechanisms of action of candidate drugs targeting viruses and host cells, and looks ahead to future trends in the development of small-molecule antiviral drugs, with the aim of providing a reference for promoting the development of new bunyavirus drugs.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly
Microorganisms in Medicine and Therapeutics
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...

